Verition Fund Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-28,766
| Closed | -$4.08M | – | 3113 |
|
|
2025
Q4 | $4.08M | Sell |
28,766
-9,907
| -26% | -$1.44M | 0.02% | 1031 |
|
|
2025
Q3 | $5.43M | Sell |
38,673
-9,422
| -20% | -$1.28M | 0.02% | 1074 |
|
|
2025
Q2 | $6.05M | Buy |
48,095
+30,099
| +167% | +$3.45M | 0.03% | 929 |
|
|
2025
Q1 | $1.99M | Buy |
17,996
+7,301
| +68% | +$925K | 0.01% | 1574 |
|
|
2024
Q4 | $1.46M | Buy |
10,695
+2,370
| +28% | +$293K | 0.01% | 1776 |
|
|
2024
Q3 | $959K | Buy |
+8,325
| New | +$1.14M | ﹤0.01% | 1915 |
|
|
2024
Q2 | – | Sell |
-4,202
| Closed | -$580K | – | 3168 |
|
|
2024
Q1 | $580K | Buy |
4,202
+2,305
| +122% | +$315K | ﹤0.01% | 1937 |
|
|
2023
Q4 | $250K | Sell |
1,897
-38,782
| -95% | -$4.46M | ﹤0.01% | 1892 |
|
|
2023
Q3 | $4.58M | Sell |
40,679
-3,773
| -8% | -$397K | 0.05% | 477 |
|
|
2023
Q2 | $4.19M | Sell |
44,452
-25,110
| -36% | -$2.45M | 0.06% | 421 |
|
|
2023
Q1 | $7.04M | Buy |
69,562
+64,796
| +1,360% | +$6.74M | 0.1% | 272 |
|
|
2022
Q4 | $569K | Buy |
4,766
+1,922
| +68% | +$225K | 0.01% | 1175 |
|
|
2022
Q3 | $302K | Sell |
2,844
-946
| -25% | -$96K | ﹤0.01% | 2226 |
|
|
2022
Q2 | $369K | Sell |
3,790
-99,744
| -96% | -$9.21M | 0.01% | 1617 |
|
|
2022
Q1 | $9.71M | Buy |
+103,534
| New | +$8.77M | 0.12% | 162 |
|
|
2021
Q3 | – | Sell |
-42,738
| Closed | -$4.16M | – | 2179 |
|
|
2021
Q2 | $4.16M | Buy |
42,738
+36,323
| +566% | +$3.48M | 0.04% | 281 |
|
|
2021
Q1 | $624K | Sell |
6,415
-97,953
| -94% | -$10.3M | 0.01% | 760 |
|
|
2020
Q4 | $10M | Buy |
104,368
+99,223
| +1,929% | +$9.58M | 0.09% | 131 |
|
|
2020
Q3 | $495K | Buy |
5,145
+2,543
| +98% | +$294K | 0.01% | 580 |
|
|
2020
Q2 | $317K | Buy |
+2,602
| New | +$288K | 0.01% | 781 |
|
|
2020
Q1 | – | Sell |
-15,216
| Closed | -$1.64M | – | 904 |
|
|
2019
Q4 | $1.64M | Buy |
15,216
+12,202
| +405% | +$1.28M | 0.03% | 310 |
|
|
2019
Q3 | $272K | Buy |
+3,014
| New | +$282K | 0.01% | 837 |
|
|
2019
Q2 | – | Sell |
-3,844
| Closed | -$339K | – | 1266 |
|
|
2019
Q1 | $339K | Buy |
+3,844
| New | +$321K | 0.01% | 792 |
|
|
2018
Q4 | – | Sell |
-28,801
| Closed | -$3.54M | – | 1107 |
|
|
2018
Q3 | $3.54M | Buy |
+28,801
| New | +$3.27M | 0.13% | 148 |
|
|
2018
Q2 | – | Sell |
-4,337
| Closed | -$360K | – | 1243 |
|
|
2018
Q1 | $360K | Sell |
4,337
-4,024
| -48% | -$340K | 0.03% | 747 |
|
|
2017
Q4 | $649K | Buy |
+8,361
| New | +$570K | 0.06% | 394 |
|
Other funds holding NBIX
VPM
VCM
Verition Fund Management's NBIX Position: Q1 2026 in Review
Verition Fund Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 28,766 shares — an estimated $4.08M sold.
Verition Fund Management first reported a position in NBIX in Q4 2017 and held it in 26 quarters. The position peaked at $10M in Q4 2020. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Verition Fund Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
- Verition Fund Management sold 28,766 Neurocrine Biosciences shares in Q1 2026, an estimated $4.08M.
- Verition Fund Management first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 26 quarters.
- Verition Fund Management's Neurocrine Biosciences position peaked at $10M in Q4 2020.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.